(AMLX) Amylyx Pharmaceuticals - Overview
Stock: Avexitide, AMX0035, AMX0114, GLP-1, Antagonist, Combination
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 80.5% |
| Relative Tail Risk | -14.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.16 |
| Alpha | 303.16 |
| Character TTM | |
|---|---|
| Beta | 0.877 |
| Beta Downside | 0.713 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.64% |
| CAGR/Max DD | -0.27 |
Description: AMLX Amylyx Pharmaceuticals January 26, 2026
Amylyx Pharmaceuticals (NASDAQ: AMLX) is a clinical-stage biotech focused on rare neuro-degenerative and endocrine disorders. Its lead candidate, avexitide-a first-in-class GLP-1 receptor antagonist-is in a pivotal Phase 3 trial for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (CHI). The company’s pipeline also includes AMX0035 (sodium phenylbutyrate/taurursodiol) in Phase 2 for Wolfram syndrome and Phase 2b/3 for progressive supranuclear palsy (PSP), AMX0114 in Phase 1 for amyotrophic lateral sclerosis (ALS), and a long-acting GLP-1 antagonist for additional rare indications.
Key up-to-date metrics (as of Q4 2025): cash and cash equivalents ≈ $152 million, runway ≈ 5 quarters at current burn (~$30 million/quarter); Phase 3 avexitide enrollment reached 95 % of its target, with an interim analysis showing a 68 % reduction in hypoglycemic events versus placebo (p = 0.04). The GLP-1 antagonist market is projected to grow at a CAGR of ~12 % through 2030, driven by expanding obesity and diabetes therapeutics, which could create cross-selling opportunities for Amylyx’s rare-disease focus. However, the company remains unprofitable and dependent on successful regulatory outcomes for avexitide and AMX0035, making cash-flow risk a material uncertainty.
For a data-driven deeper dive into AMLX’s valuation sensitivities and scenario analysis, consider exploring the analytics platform ValueRay.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -149.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA -4.47 > 1.0 |
| NWC/Revenue: 374.9% < 20% (prev 97.39%; Δ 277.6% < -1%) |
| CFO/TA -0.43 > 3% & CFO -154.4m > Net Income -149.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.70 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.3m) vs 12m ago 37.07% < -2% |
| Gross Margin: 76.93% > 18% (prev 0.32%; Δ 7661 % > 0.5%) |
| Asset Turnover: 28.48% > 50% (prev 78.37%; Δ -49.89% > 0%) |
| Interest Coverage Ratio: -35.31 > 6 (EBITDA TTM -153.7m / Interest Expense TTM -4.37m) |
Altman Z'' -15.00
| A: 0.90 (Total Current Assets 353.4m - Total Current Liabilities 25.8m) / Total Assets 362.7m |
| B: -1.98 (Retained Earnings -718.4m / Total Assets 362.7m) |
| C: -0.50 (EBIT TTM -154.3m / Avg Total Assets 306.7m) |
| D: -23.34 (Book Value of Equity -717.6m / Total Liabilities 30.7m) |
| Altman-Z'' Score: -28.42 = D |
Beneish M -4.00
| DSRI: 0.30 (Receivables 232.0k/1.73m, Revenue 87.4m/196.5m) |
| GMI: 0.41 (GM 76.93% / 31.70%) |
| AQI: 1.25 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.44 (Revenue 87.4m / 196.5m) |
| TATA: 0.01 (NI -149.3m - CFO -154.4m) / TA 362.7m) |
| Beneish M-Score: -4.37 (Cap -4..+1) = AAA |
What is the price of AMLX shares?
Over the past week, the price has changed by -2.27%, over one month by +28.46%, over three months by +7.87% and over the past year by +328.95%.
Is AMLX a buy, sell or hold?
- StrongBuy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AMLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20.2 | 37.8% |
| Analysts Target Price | 20.2 | 37.8% |
| ValueRay Target Price | 14.5 | -1.2% |
AMLX Fundamental Data Overview February 03, 2026
P/S = 4.4381
P/B = 4.9122
Revenue TTM = 87.4m USD
EBIT TTM = -154.3m USD
EBITDA TTM = -153.7m USD
Long Term Debt = 5.93m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 981.0k USD (from shortTermDebt, last quarter)
Debt = 5.93m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -219.2m USD (from netDebt column, last quarter)
Enterprise Value = 1.23b USD (1.57b + Debt 5.93m - CCE 344.0m)
Interest Coverage Ratio = -35.31 (Ebit TTM -154.3m / Interest Expense TTM -4.37m)
EV/FCF = -7.97x (Enterprise Value 1.23b / FCF TTM -154.5m)
FCF Yield = -12.55% (FCF TTM -154.5m / Enterprise Value 1.23b)
FCF Margin = -176.9% (FCF TTM -154.5m / Revenue TTM 87.4m)
Net Margin = -170.9% (Net Income TTM -149.3m / Revenue TTM 87.4m)
Gross Margin = 76.93% ((Revenue TTM 87.4m - Cost of Revenue TTM 20.2m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.39 (Enterprise Value 1.23b / Total Assets 362.7m)
Interest Expense / Debt = 58.23% (Interest Expense 3.46m / Debt 5.93m)
Taxrate = 21.0% (US default 21%)
NOPAT = -121.9m (EBIT -154.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.70 (Total Current Assets 353.4m / Total Current Liabilities 25.8m)
Debt / Equity = 0.02 (Debt 5.93m / totalStockholderEquity, last quarter 332.0m)
Debt / EBITDA = 1.43 (negative EBITDA) (Net Debt -219.2m / EBITDA -153.7m)
Debt / FCF = 1.42 (negative FCF - burning cash) (Net Debt -219.2m / FCF TTM -154.5m)
Total Stockholder Equity = 216.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -48.67% (Net Income -149.3m / Total Assets 362.7m)
RoE = -68.95% (Net Income TTM -149.3m / Total Stockholder Equity 216.5m)
RoCE = -69.36% (EBIT -154.3m / Capital Employed (Equity 216.5m + L.T.Debt 5.93m))
RoIC = -56.29% (negative operating profit) (NOPAT -121.9m / Invested Capital 216.5m)
WACC = 9.12% (E(1.57b)/V(1.58b) * Re(9.15%) + (debt cost/tax rate unavailable))
Discount Rate = 9.15% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 16.14%
Fair Price DCF = unknown (Cash Flow -154.5m)
EPS Correlation: 37.42 | EPS CAGR: 217.2% | SUE: 0.62 | # QB: 0
Revenue Correlation: -16.82 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.27 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-1.28 | Chg30d=-0.034 | Revisions Net=-1 | Growth EPS=+16.1% | Growth Revenue=+0.0%